title: When is good good enough for HIV-1 prophylaxis?
authors.affiliation: San Francisco Department of Public Health, San Francisco, CA, USA. Electronic address: susan.buchbinder@sfdph.org.
authors.forename: Susan
authors.initials: S
authors.lastname: Buchbinder
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068679:Emtricitabine; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D065129:Pre-Exposure Prophylaxis / Q000379:methods*; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D003841:Deoxycytidine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine